Orakl Oncology (Seed)
Funding Details
- Awarder
- Inbox
- Date Award
- December 03, 2024
- Vertical
- Healthtech
- Funding URL
- View Funding Page
- Funding Amount:
- $11,000,000
Company Info
- Founding Year
- 2023
- Traction
- Orakl plans to launch two new commercial products, O-Predict and O-Validate, to enhance drug development.
- Organizations Involved
- Gustave Roussy
- Founders
- Fanny Jaulin, Diane-Laure Pagès, Gustave Ronteix
- Company Description
- Orakl Oncology is a precision oncology company that has developed an AI-powered techbio platform combining real-world patient data with biology to improve drug development processes.
- Market
- Precision Oncology
- Location
- France
- Coinvestors
- Singular, Bpifrance